佛慈制药
(002644)
| 流通市值：38.96亿 | | | 总市值：38.96亿 |
| 流通股本：5.11亿 | | | 总股本：5.11亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 650,224,311.46 | 440,320,280.34 | 211,574,701.05 | 915,533,598.79 |
| 营业收入 | 650,224,311.46 | 440,320,280.34 | 211,574,701.05 | 915,533,598.79 |
| 二、营业总成本 | 590,151,686.86 | 394,915,425.87 | 183,095,248.39 | 813,851,221.73 |
| 营业成本 | 440,154,356.69 | 294,160,381.19 | 133,022,807.41 | 603,416,413.47 |
| 税金及附加 | 10,521,998.69 | 7,115,520.51 | 3,395,052.25 | 15,569,775.55 |
| 销售费用 | 73,676,693.83 | 49,301,480.28 | 25,448,178.66 | 102,357,944.28 |
| 管理费用 | 54,362,234.66 | 37,077,806.16 | 17,697,049.71 | 72,856,748.17 |
| 研发费用 | 15,345,649.57 | 9,964,562.97 | 4,755,874.56 | 24,555,383.4 |
| 财务费用 | -3,909,246.58 | -2,704,325.24 | -1,223,714.2 | -4,905,043.14 |
| 其中:利息费用 | 1,137,782.56 | 548,392.88 | - | 770,722.73 |
| 其中:利息收入 | 5,037,152.38 | 3,229,477.69 | - | 5,897,953.91 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -5,867,291.46 | -3,164,415.78 | -2,020,001.15 | -13,537,423.9 |
| 资产处置收益 | - | - | 0 | 7,131,603.77 |
| 资产减值损失(新) | -350.44 | - | - | -1,793,611.93 |
| 信用减值损失(新) | -8,232,506.73 | -7,457,061.83 | -4,835,911.52 | -56,646,435.06 |
| 其他收益 | 17,124,087.58 | 10,913,870.36 | 5,501,440.35 | 29,148,994.55 |
| 四、营业利润 | 63,096,563.55 | 45,697,247.22 | 27,124,980.34 | 65,985,504.49 |
| 加:营业外收入 | 254,151.72 | 211,025.24 | 10,972.83 | 829,998.65 |
| 减:营业外支出 | 3,471,669.98 | 1,492,066.4 | 103,055.95 | 1,785,074.13 |
| 五、利润总额 | 59,879,045.29 | 44,416,206.06 | 27,032,897.22 | 65,030,429.01 |
| 减:所得税费用 | 10,558,691.73 | 6,460,470.48 | 4,161,283.51 | 18,075,412.57 |
| 六、净利润 | 49,320,353.56 | 37,955,735.58 | 22,871,613.71 | 46,955,016.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 49,320,353.56 | 37,955,735.58 | 22,871,613.71 | 46,955,016.44 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 50,721,111.64 | 39,738,459.63 | 22,661,247.41 | 49,207,166.39 |
| 少数股东损益 | -1,400,758.08 | -1,782,724.05 | 210,366.3 | -2,252,149.95 |
| 扣除非经常损益后的净利润 | 38,303,942.23 | 31,009,018.99 | 18,056,674.65 | 20,239,831.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.08 | 0.04 | 0.1 |
| (二)稀释每股收益 | 0.1 | 0.08 | 0.04 | 0.1 |
| 八、其他综合收益 | -156,937.64 | -156,937.64 | - | -90,160.47 |
| 归属于母公司股东的其他综合收益 | -80,920.97 | -80,920.97 | - | -46,488.99 |
| 九、综合收益总额 | 49,163,415.92 | 37,798,797.94 | 22,871,613.71 | 46,864,855.97 |
| 归属于母公司股东的综合收益总额 | 50,640,190.67 | 39,657,538.66 | 22,661,247.41 | 49,160,677.4 |
| 归属于少数股东的综合收益总额 | -1,476,774.75 | -1,858,740.72 | 210,366.3 | -2,295,821.43 |
| 公告日期 | 2026-10-29 | 2026-08-20 | 2026-04-30 | 2026-04-09 |
| 审计意见(境内) | | | | 标准无保留意见 |